Unknown

Dataset Information

0

Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata.

ABSTRACT: A bioactivity guided study of a cf. Caldora penicillata species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1) was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell lung cancer cells in vitro.

SUBMITTER: Zhang C 

PROVIDER: S-EPMC5408267 | biostudies-other | 2017 Apr

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata.

Zhang Chen C   Naman C Benjamin CB   Engene Niclas N   Gerwick William H WH  

Marine drugs 20170414 4

A bioactivity guided study of a cf. <i>Caldora penicillata</i> species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (<b>1</b>). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (<b>2</b>), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacter  ...[more]